Literature DB >> 35649410

A direct high-throughput protein quantification strategy facilitates discovery and characterization of a celastrol-derived BRD4 degrader.

N Connor Payne1, Semer Maksoud2, Bakhos A Tannous2, Ralph Mazitschek3.   

Abstract

We describe a generalizable time-resolved Förster resonance energy transfer (TR-FRET)-based platform to profile the cellular action of heterobifunctional degraders (or proteolysis-targeting chimeras [PROTACs]) that is capable of both accurately quantifying protein levels in whole-cell lysates in less than 1 h and measuring small-molecule target engagement to endogenous proteins, here specifically for human bromodomain-containing protein 4 (BRD4). The detection mix consists of a single primary antibody targeting the protein of interest, a luminescent donor-labeled anti-species nanobody, and a fluorescent acceptor ligand. Importantly, our strategy can readily be applied to other targets of interest and will greatly facilitate the cell-based profiling of small-molecule inhibitors and PROTACs in a high-throughput format with unmodified cell lines. We furthermore validate our platform in the characterization of celastrol, a p-quinone methide-containing pentacyclic triterpenoid, as a broad cysteine-targeting E3 ubiquitin ligase warhead for potent and efficient targeted protein degradation.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  PROTAC; TR-FRET; celastrol; covalent; degrader; high-throughput; protein quantification; reversible; small molecules; targeted protein degradation

Mesh:

Substances:

Year:  2022        PMID: 35649410      PMCID: PMC9391279          DOI: 10.1016/j.chembiol.2022.05.003

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   9.039


  33 in total

Review 1.  Targeted protein degradation: current and future challenges.

Authors:  Alexander Hanzl; Georg E Winter
Journal:  Curr Opin Chem Biol       Date:  2020-01-02       Impact factor: 8.822

2.  Targeted protein degradation: expanding the toolbox.

Authors:  Matthieu Schapira; Matthew F Calabrese; Alex N Bullock; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2019-10-30       Impact factor: 84.694

Review 3.  Development of targeted protein degradation therapeutics.

Authors:  Philip P Chamberlain; Lawrence G Hamann
Journal:  Nat Chem Biol       Date:  2019-09-16       Impact factor: 15.040

Review 4.  Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases.

Authors:  Antonio Cuadrado; Ana I Rojo; Geoffrey Wells; John D Hayes; Sharon P Cousin; William L Rumsey; Otis C Attucks; Stephen Franklin; Anna-Liisa Levonen; Thomas W Kensler; Albena T Dinkova-Kostova
Journal:  Nat Rev Drug Discov       Date:  2019-04       Impact factor: 84.694

5.  Bright and stable luminescent probes for target engagement profiling in live cells.

Authors:  N Connor Payne; Alena S Kalyakina; Kritika Singh; Mark A Tye; Ralph Mazitschek
Journal:  Nat Chem Biol       Date:  2021-10-21       Impact factor: 15.040

6.  CRISPR-Mediated Tagging of Endogenous Proteins with a Luminescent Peptide.

Authors:  Marie K Schwinn; Thomas Machleidt; Kris Zimmerman; Christopher T Eggers; Andrew S Dixon; Robin Hurst; Mary P Hall; Lance P Encell; Brock F Binkowski; Keith V Wood
Journal:  ACS Chem Biol       Date:  2017-09-21       Impact factor: 5.100

7.  Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.

Authors:  Emily J Faivre; Keith F McDaniel; Daniel H Albert; Srinivasa R Mantena; Joshua P Plotnik; Denise Wilcox; Lu Zhang; Mai H Bui; George S Sheppard; Le Wang; Vasudha Sehgal; Xiaoyu Lin; Xiaoli Huang; Xin Lu; Tamar Uziel; Paul Hessler; Lloyd T Lam; Richard J Bellin; Gaurav Mehta; Steve Fidanze; John K Pratt; Dachun Liu; Lisa A Hasvold; Chaohong Sun; Sanjay C Panchal; John J Nicolette; Stacey L Fossey; Chang H Park; Kenton Longenecker; Lance Bigelow; Maricel Torrent; Saul H Rosenberg; Warren M Kati; Yu Shen
Journal:  Nature       Date:  2020-01-22       Impact factor: 49.962

8.  BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.

Authors:  Georg E Winter; Andreas Mayer; Dennis L Buckley; Michael A Erb; Justine E Roderick; Sarah Vittori; Jaime M Reyes; Julia di Iulio; Amanda Souza; Christopher J Ott; Justin M Roberts; Rhamy Zeid; Thomas G Scott; Joshiawa Paulk; Kate Lachance; Calla M Olson; Shiva Dastjerdi; Sophie Bauer; Charles Y Lin; Nathanael S Gray; Michelle A Kelliher; L Stirling Churchman; James E Bradner
Journal:  Mol Cell       Date:  2017-06-29       Impact factor: 17.970

Review 9.  High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics.

Authors:  Jeffrey R Simard; Linda Lee; Ellen Vieux; Reina Improgo; Trang Tieu; Andrew J Phillips; Stewart L Fisher; Roy M Pollock; Eunice Park
Journal:  SLAS Discov       Date:  2021-01-11       Impact factor: 3.341

10.  Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.

Authors:  Marie Jung; Martin Philpott; Susanne Müller; Jessica Schulze; Volker Badock; Uwe Eberspächer; Dieter Moosmayer; Benjamin Bader; Norbert Schmees; Amaury Fernández-Montalván; Bernard Haendler
Journal:  J Biol Chem       Date:  2014-02-04       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.